Duragesic Pediatric Exclusivity Decision Expected “Shortly,” Mylan Says
Executive Summary
Mylan expects to hear from FDA "shortly" on whether its generic version of Johnson & Johnson's Duragesic fentanyl patch will be delayed an additional six months due to a pediatric exclusivity extension
You may also be interested in...
Mylan Loses Duragesic Case; Generic Launch Timing Dispute Moves To FDA
The launch timing for the first generic version of Johnson & Johnson/Alza's Duragesic fentanyl patch will depend on FDA's decision about a six-month pediatric exclusivity extension for the product
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials